Dr Gill Harinder Harry Singh
|2006||The University of Hong Kong||MBBS|
|2009||Royal College of Physicians||MRCP (UK)|
|2009||The University of Hong Kong||PDipID|
|2013||Hong Kong College of Phycicians||FHKCP|
|2013||The Hong Kong Academy of Medicine||FHKAM (Medicine)|
|2018||Royal College of Physicians of Edinburgh||FRCP (Edin)|
|2018||Royal College of Physicians and Surgeons of Glasgow||FRCP (Glasg)|
|2019||Royal College of Pathologists||FRCPath|
|2019||The University of Hong Kong||MD|
|2020||Royal College of Physicians||FRCP (Lond)|
|2013||Hong Kong College of Physicians||FHKCP|
|2013||Hong Kong College of Physicians||FHKCP|
Dr. Gill Harinder Singh Harry graduated from the University of Hong Kong in 2006 and joined the Department of Medicine, Queen Mary Hospital in July 2007. He joined the University of Hong Kong as Clinical Assistant Professor in July 2014 and completed his training in Haematology and Haematological Oncology, and Advanced Internal Medicine in 2013 and 2014, respectively. He also underwent training in Haematopathology at the Department of Pathology, Queen Mary Hospital from 2017 to 2019 and was conferred Fellow of The Royal College of Pathologists in February 2019. He completed his doctorate degree in 2019 focusing on the genomics of myeloproliferative neoplasms. He has published extensively in esteemed peer-reviewed journals, including Blood, Blood Advances, Haematologica, British Journal of Haematology, Bone Marrow Transplantation, Annals of Oncology, Journal of Clinical Oncology, Cancer and Science Translational Medicine. He is the service-lead for acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN) in Queen Mary Hospital, Hong Kong.
One of his key research areas since 2010 is the application of oral arsenic trioxide in the treatment of acute promyelocytic leukaemia (APL) and other haematological malignancies. Important practice-changing observations were made. He showed that a second complete remission rate of 100% and 10-year overall survival of more than 80% can be achieved in relapsed APL with oral arsenic trioxide-based regimen without hematopoietic stem cell transplantation (HSCT). His work on frontline oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid-based induction in newly diagnosed APL has also shown 100% complete remission rate with a 5-year leukaemia-free and overall survival of 100%, showing that a universal cure is achieved with the frontline oral arsenic trioxide-based regimen in APL. This is also the first study employing arsenic trioxide in its oral formulation worldwide. In another ongoing multicentre study, a completely chemotherapy-free and oral regimen for APL is being evaluated. He steered the research and development, and the clinical use of the Good Manufacturing Practice (GMP) grade oral arsenic trioxide (Arsenol ®), the first GMP grade oral formulation of arsenic trioxide worldwide.
Dr. Gill also leads research on MDS and MPN with specific focus on molecular alterations and novel therapeutics in these disorders. He is currently leading studies on the genomics of clonal haematopoiesis, MDS, secondary AML and MPN. He is also one of the key investigators of several global phase 2 and 3 studies evaluating the use of novel targeted therapy and immunotherapy in MDS and MPN.
He is one of the founding members and directors of the Asian Myeloid Working Group leading key regional studies on myeloid malignancies in Asia including the Asian MDS Genomics Registry, the APL Asian Consortium Study and the Asian MPN Registry.
|Awardees||Award Date||Honours / Awards / Prizes||Category|
|2013-12-01||Best Original Research by Trainees 2013 (Bronze Medal): Hong Kong Academy of Medicine||Research Achievement|
|2013-10-01||Young Investigator Research Grant 2013: Hong Kong College of Physicians||Research Achievement|
|2013-01-01||Best Abstract in Clinical Medicine, 18th Medical Research Conference: Department of Medicine, the University of Hong Kong||Research Achievement|
|2014-05-01||Best Abstract Award, Hong Kong Society of Haematology Annual Scientific Meeting 2013: Hong Kong Society of Haematology||Research Achievement|
|2013-12-01||Faculty Knowledge Exchange (KE) Award 2013: 'Multi-media Haematology Protocol: Haematology Protocol Book, iPad/iPhone App, Internet Website' (Group Award): The University of Hong Kong||Teaching Accomplishment|
|2013-06-01||Training and Research Assistance Scheme 2013: Queen Mary Hospital Charitable Trust||Research Achievement|
|2014-05-01||Best Abstract Award, Hong Kong Society of Haematology, Annual Scientific Meeting 2014: Hong Kong Society of Haematology||Research Achievement|
|2014-10-01||Highest Score in Advanced Internal Medicine Exit Assessment: Hong Kong College of Physicians||Others|
|2015-03-01||Best Paper Award - the Hong Kong Society of Haematology Annual Scientific Meeting 2015: The Hong Kong Society of Haematology||Research Achievement|
|2017-01-01||Best Abstract Award in Clinical Medicine: 22nd Medical Research Conference, Department of Medicine, HKU.||Research Achievement|
|2017-09-01||Faculty Outstanding Research Output Award: Li Ka Shing Faculty of Medicine, the University of Hong Kong||Research Achievement|
|2018-01-01||Best Abstract in Clinical Medicine, Medical Research Conference 2018.: Department of Medicine, LKS Faculty of Medicine, the University of Hong Kong.||Research Achievement|
|Term Period||Position||Professional Societies|
|03/2021 - present||Director and Founding Member||Asian Myeloid Working Group|
|07/2014 - present||Member||American Society of Haematology|
|07/2014 - present||Member||European Haematology Association|
|07/2010 - present||Member||Hong Kong Society of Haematology|
Are You Missing Publications, Invited Lectures? Click Me.